Citius Pharmaceuticals, Inc. Investment Income, Interest
Citius Pharmaceuticals, Inc. (CTXR) reported Investment Income, Interest of $116.69 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $116.69K, a 465.45% increase year-over-year.
- Citius Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $53.58K, a 299.49% increase year-over-year.
- Citius Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $45.10K, a 99.47% increase year-over-year.
- Citius Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $53.42K, a 54.46% decline year-over-year.
- Citius Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $110.08K, a 85.48% decline from fiscal 2024.
- Citius Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $758.00K, a 35.73% decline from fiscal 2023.
- Citius Pharmaceuticals, Inc. investment income, interest for fiscal 2023 was $1.18M, a 369.14% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. investment income, interest for fiscal 2022 was $251.40K, a 3.98% decline from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $116.69K 10-Q · filed 2026-08-14 | $170.28K derived: sum of 2 quarters · filed 2026-08-14 | $215.37K 10-Q · filed 2026-08-14 | $268.80K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $53.58K 10-Q · filed 2026-05-15 | $98.68K 10-Q · filed 2026-05-15 | $152.10K derived: sum of 3 quarters · filed 2026-05-15 | $172.74K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $45.10K 10-Q · filed 2026-02-13 | $98.52K derived: sum of 2 quarters · filed 2026-02-13 | $119.16K derived: sum of 3 quarters · filed 2026-08-14 | $132.57K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $53.42K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $74.06K derived: sum of 2 quarters · filed 2026-08-14 | $87.47K derived: sum of 3 quarters · filed 2026-08-14 | $110.08K 10-K · filed 2025-12-23 |
| 2025-06-30 | $20.64K 10-Q · filed 2026-08-14 | $34.05K derived: sum of 2 quarters · filed 2026-08-14 | $56.66K 10-Q · filed 2026-08-14 | $173.97K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $13.41K 10-Q · filed 2026-05-15 | $36.02K 10-Q · filed 2026-05-15 | $153.34K derived: sum of 3 quarters · filed 2026-05-15 | $358.18K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $22.61K 10-Q · filed 2026-02-13 | $139.92K derived: sum of 2 quarters · filed 2026-02-13 | $344.76K derived: sum of 3 quarters · filed 2026-02-13 | $526.97K derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $117.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $322.16K derived: sum of 2 quarters · filed 2025-12-23 | $504.36K derived: sum of 3 quarters · filed 2025-12-23 | $758.00K 10-K · filed 2025-12-23 |
| 2024-06-30 | $204.84K 10-Q · filed 2025-08-12 | $387.05K derived: sum of 2 quarters · filed 2025-08-12 | $640.69K 10-Q · filed 2025-08-12 | $965.50K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $182.21K 10-Q · filed 2025-05-14 | $435.84K 10-Q · filed 2025-05-14 | $760.66K derived: sum of 3 quarters · filed 2025-05-14 | $1.10M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $253.64K 10-Q · filed 2025-02-14 | $578.45K derived: sum of 2 quarters · filed 2025-02-14 | $915.23K derived: sum of 3 quarters · filed 2025-02-14 | $1.22M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $324.81K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $661.59K derived: sum of 2 quarters · filed 2024-12-27 | $964.87K derived: sum of 3 quarters · filed 2024-12-27 | $1.18M 10-K · filed 2024-12-27 |
| 2023-06-30 | $336.78K 10-Q · filed 2024-08-12 | $640.05K derived: sum of 2 quarters · filed 2024-08-12 | $854.60K 10-Q · filed 2024-08-12 | $989.43K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $303.27K 10-Q · filed 2024-05-14 | $517.82K 10-Q · filed 2024-05-14 | $652.65K derived: sum of 3 quarters · filed 2024-05-14 | $705.67K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $214.55K 10-Q · filed 2024-02-14 | $349.38K derived: sum of 2 quarters · filed 2024-02-14 | $402.39K derived: sum of 3 quarters · filed 2024-02-14 | $431.97K derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | $134.83K derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $187.85K derived: sum of 2 quarters · filed 2023-12-29 | $217.42K derived: sum of 3 quarters · filed 2023-12-29 | $251.40K 10-K · filed 2023-12-29 |
| 2022-06-30 | $53.02K 10-Q · filed 2023-08-14 | $82.59K derived: sum of 2 quarters · filed 2023-08-14 | $116.57K 10-Q · filed 2023-08-14 | $192.17K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $29.57K 10-Q · filed 2023-05-12 | $63.55K 10-Q · filed 2023-05-12 | $139.15K derived: sum of 3 quarters · filed 2023-05-12 | $242.57K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $33.98K 10-Q · filed 2023-02-10 | $109.58K derived: sum of 2 quarters · filed 2023-02-10 | $213.00K derived: sum of 3 quarters · filed 2023-02-10 | $282.32K derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-09-30 | $75.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $179.01K derived: sum of 2 quarters · filed 2022-12-22 | $248.34K derived: sum of 3 quarters · filed 2022-12-22 | $261.82K 10-K · filed 2022-12-22 |
| 2021-06-30 | $103.41K 10-Q · filed 2022-08-11 | $172.74K derived: sum of 2 quarters · filed 2022-08-11 | $186.22K 10-Q · filed 2022-08-11 | $209.83K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $69.33K 10-Q · filed 2022-05-12 | $82.81K 10-Q · filed 2022-05-12 | $106.41K derived: sum of 3 quarters · filed 2022-05-12 | $119.43K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.48K 10-Q · filed 2022-02-10 | $37.09K derived: sum of 2 quarters · filed 2022-02-10 | $50.10K derived: sum of 3 quarters · filed 2022-02-10 | $62.21K derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-09-30 | $23.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | $36.62K derived: sum of 2 quarters · filed 2021-12-15 | $48.73K derived: sum of 3 quarters · filed 2021-12-15 | $68.07K 10-K · filed 2021-12-15 |
| 2020-06-30 | $13.02K 10-Q · filed 2021-08-12 | $25.12K derived: sum of 2 quarters · filed 2021-08-12 | $44.46K 10-Q · filed 2021-08-12 | $55.96K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $12.11K 10-Q · filed 2021-05-13 | $31.45K 10-Q · filed 2021-05-13 | $42.95K derived: sum of 3 quarters · filed 2021-05-13 | $68.21K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $19.34K 10-Q · filed 2021-02-11 | $30.84K derived: sum of 2 quarters · filed 2021-02-11 | $56.11K derived: sum of 3 quarters · filed 2021-02-11 | $70.25K derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-09-30 | $11.50K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-16 | $36.77K derived: sum of 2 quarters · filed 2020-12-16 | $50.91K derived: sum of 3 quarters · filed 2020-12-16 | $52.66K 10-K · filed 2020-12-16 |
| 2019-06-30 | $25.27K 10-Q · filed 2020-08-14 | $39.41K derived: sum of 2 quarters · filed 2020-08-14 | $41.16K 10-Q · filed 2020-08-14 | |
| 2019-03-31 | $14.14K 10-Q · filed 2020-05-14 | $15.89K 10-Q · filed 2020-05-14 | ||
| 2018-12-31 | $1.75K 10-Q · filed 2020-02-13 | |||
| 2016-09-30 | $806.00 10-K · filed 2018-12-11 | |||
| 2015-09-30 | $3.07K 10-K · filed 2017-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |